Abstract
Background This study aimed to calculate the seroconversion rate of the CoronaVac vaccine in healthcare workers (HCWs) 40 days after administration.
Methods Serum samples from 133 HCWs from Southern Brazil were collected one day before (Day 0) and 10, 20, and 40 days after administering the vaccine’s first dose. Immunoglobulin G (IgG) was quantified using immunoassays for anti-N-protein antibodies (Abbott, Sligo, Ireland) and for anti-S1 (spike) protein antibodies (Euroimmun, Lübeck, Germany).
Results Seroconversion by D 40 (20 days after the second dose) occurred in 129 (97%) HCWs for the S1 protein, and in 69 (51.87%) HCWs for the N protein. An absence of IgG antibodies (by both methodologies), occurred in two (1.5%) HCWs undergoing semiannual rituximab administration, and also in another two (1.5%) HCWs with no apparent reason.
Conclusion This study showed that CoronaVac has a high seroconversion rate when evaluated in an HCW population.
Funding This work was supported by the PROPLAN/Federal University of Paraná, Curitiba-Paraná, Brazil; FINEP, Funder of Studies and Projects, Ministry of Science, Technology and Innovation, Brazil Institutional Network, Project: Laboratories for Diagnostic Tests for COVID-19 (0494/20).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the PROPLAN/Federal University of Parana, Curitiba-Parana, Brazil; FINEP, Funder of Studies and Projects, Ministry of Science, Technology and Innovation, Brazil Institutional Network, Project: Laboratories for Diagnostic Tests for COVID-19 (0494/20).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In total, 170 participants were recruited at the Complexo Hospital de Clinicas, UFPR, Clinical Laboratory, Curitiba, Brazil, during the vaccination of healthcare worker in this city. The Complexo Hospital de Clinicas, UFPR, Institutional Ethical Committee approved the study (CAAE: 31687620.2.0000.0096), and all participants signed their consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available with the corresponding author.
